Logo image of ARDX

ARDELYX INC (ARDX) Stock Fundamental Analysis

NASDAQ:ARDX - US0396971071 - Common Stock

6.575 USD
+0.06 (+0.84%)
Last: 9/8/2025, 12:20:43 PM
Fundamental Rating

3

Taking everything into account, ARDX scores 3 out of 10 in our fundamental rating. ARDX was compared to 541 industry peers in the Biotechnology industry. ARDX has a bad profitability rating. Also its financial health evaluation is rather negative. ARDX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ARDX has reported negative net income.
ARDX had a negative operating cash flow in the past year.
In the past 5 years ARDX always reported negative net income.
ARDX had a negative operating cash flow in each of the past 5 years.
ARDX Yearly Net Income VS EBIT VS OCF VS FCFARDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ARDX (-12.03%) is better than 82.62% of its industry peers.
The Return On Equity of ARDX (-40.11%) is better than 71.53% of its industry peers.
Industry RankSector Rank
ROA -12.03%
ROE -40.11%
ROIC N/A
ROA(3y)-22.15%
ROA(5y)-43.75%
ROE(3y)-43.48%
ROE(5y)-79.34%
ROIC(3y)N/A
ROIC(5y)N/A
ARDX Yearly ROA, ROE, ROICARDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ARDX has a Gross Margin of 84.80%. This is amongst the best in the industry. ARDX outperforms 87.62% of its industry peers.
ARDX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ARDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
ARDX Yearly Profit, Operating, Gross MarginsARDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARDX has been increased compared to 1 year ago.
The number of shares outstanding for ARDX has been increased compared to 5 years ago.
ARDX has a worse debt/assets ratio than last year.
ARDX Yearly Shares OutstandingARDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ARDX Yearly Total Debt VS Total AssetsARDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ARDX has an Altman-Z score of 1.31. This is a bad value and indicates that ARDX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ARDX (1.31) is better than 64.14% of its industry peers.
A Debt/Equity ratio of 1.44 is on the high side and indicates that ARDX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.44, ARDX is not doing good in the industry: 79.11% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.44
Debt/FCF N/A
Altman-Z 1.31
ROIC/WACCN/A
WACC9.85%
ARDX Yearly LT Debt VS Equity VS FCFARDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.29 indicates that ARDX has no problem at all paying its short term obligations.
The Current ratio of ARDX (4.29) is comparable to the rest of the industry.
A Quick Ratio of 4.02 indicates that ARDX has no problem at all paying its short term obligations.
ARDX's Quick ratio of 4.02 is in line compared to the rest of the industry. ARDX outperforms 48.06% of its industry peers.
Industry RankSector Rank
Current Ratio 4.29
Quick Ratio 4.02
ARDX Yearly Current Assets VS Current LiabilitesARDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.70% over the past year.
ARDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 83.88%.
ARDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.15% yearly.
EPS 1Y (TTM)13.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)83.88%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%33.38%

3.2 Future

ARDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.45% yearly.
ARDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.82% yearly.
EPS Next Y-122.2%
EPS Next 2Y53.4%
EPS Next 3Y77.77%
EPS Next 5Y58.46%
Revenue Next Year16.29%
Revenue Next 2Y22.27%
Revenue Next 3Y24.4%
Revenue Next 5Y21.83%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARDX Yearly Revenue VS EstimatesARDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
ARDX Yearly EPS VS EstimatesARDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ARDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ARDX is valuated quite expensively with a Price/Forward Earnings ratio of 114.25.
Based on the Price/Forward Earnings ratio, ARDX is valued cheaply inside the industry as 87.80% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.66. ARDX is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 114.25
ARDX Price Earnings VS Forward Price EarningsARDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDX Per share dataARDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ARDX's earnings are expected to grow with 77.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.4%
EPS Next 3Y77.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARDELYX INC

NASDAQ:ARDX (9/8/2025, 12:20:43 PM)

6.575

+0.06 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners73.03%
Inst Owner Change3.23%
Ins Owners2.23%
Ins Owner Change4.63%
Market Cap1.58B
Analysts86.67
Price Target11.41 (73.54%)
Short Float %10.07%
Short Ratio5.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.71%
Min EPS beat(2)-46.66%
Max EPS beat(2)41.25%
EPS beat(4)3
Avg EPS beat(4)103.02%
Min EPS beat(4)-46.66%
Max EPS beat(4)323.5%
EPS beat(8)6
Avg EPS beat(8)72.17%
EPS beat(12)9
Avg EPS beat(12)548.58%
EPS beat(16)11
Avg EPS beat(16)410.93%
Revenue beat(2)1
Avg Revenue beat(2)5.14%
Min Revenue beat(2)-7.8%
Max Revenue beat(2)18.08%
Revenue beat(4)3
Avg Revenue beat(4)6.25%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)18.08%
Revenue beat(8)6
Avg Revenue beat(8)27.86%
Revenue beat(12)10
Avg Revenue beat(12)31.92%
Revenue beat(16)12
Avg Revenue beat(16)25.31%
PT rev (1m)1.65%
PT rev (3m)8.37%
EPS NQ rev (1m)32.52%
EPS NQ rev (3m)-11.06%
EPS NY rev (1m)11.95%
EPS NY rev (3m)6.78%
Revenue NQ rev (1m)7.29%
Revenue NQ rev (3m)3.08%
Revenue NY rev (1m)6.11%
Revenue NY rev (3m)4.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 114.25
P/S 4.1
P/FCF N/A
P/OCF N/A
P/B 11.32
P/tB 11.32
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)0.06
Fwd EY0.88%
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS1.6
BVpS0.58
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.03%
ROE -40.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.8%
FCFM N/A
ROA(3y)-22.15%
ROA(5y)-43.75%
ROE(3y)-43.48%
ROE(5y)-79.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
F-Score4
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 1.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 74.67%
Cap/Sales 0.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.29
Quick Ratio 4.02
Altman-Z 1.31
F-Score4
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)26.88%
Cap/Depr(5y)45.62%
Cap/Sales(3y)0.23%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-122.2%
EPS Next 2Y53.4%
EPS Next 3Y77.77%
EPS Next 5Y58.46%
Revenue 1Y (TTM)83.88%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%33.38%
Revenue Next Year16.29%
Revenue Next 2Y22.27%
Revenue Next 3Y24.4%
Revenue Next 5Y21.83%
EBIT growth 1Y33.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-80.56%
EBIT Next 3Y96.81%
EBIT Next 5Y63.27%
FCF growth 1Y21.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.59%
OCF growth 3YN/A
OCF growth 5YN/A